CADILA HEALTHCARE LTD. - 532321 - Cadila Healthcare Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Cadila Healthcare Ltd with respect to news article https://economictimes.indiatimes.com/ June 04, 2021 titled "Zydus Cadila, first Indian Company gets permission for clinical trials of antibodies cocktail to treat COVID-19: Sources", Cadila Healthcare Ltd response is enclosed. Cadila Healthcare Ltd - 532321 - Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article https://economictimes.indiatimes.com/ June 04, 2021 titled "Zydus Cadila, first Indian Company gets permission for clinical trials of antibodies cocktail to treat COVID-19: Sources".The reply is awaited. Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Notice of loss of share certificate of the Company, published in the Financial Express. Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives tentative approval from USFDA for Osimertinib Tablets
Hold Cadila Healthcare; target of Rs 640: ICICI Direct
ICICI Direct recommended hold rating on Cadila Healthcare with a target price of Rs 640 in its research report dated May 28, 2021.
Buy Cadila Healthcare; target of Rs 740: Motilal Oswal
Motilal Oswal is bullish on Cadila Healthcare recommended buy rating on the stock with a target price of Rs 740 in its research report dated May 28, 2021.
COVID-19: Zydus Cadila plans trials for its vaccine in 5-12 years age group
Patel said vaccine developement takes place in phases, starting with adults, followed by 12-18 years age group and then for under 12 years children.
Zydus Cadila receives USFDA approval to market generic drug
The company has received approval from the US Food and Drug Administration (USFDA) to market in the US its generic version in strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg, Zydus Cadila said in a statement Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from USFDA for Fluphenazine Hydrochloride Tablets
